Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease

Table 1 Characteristics of subjects.

Fibrosis	n	M/F	Age (yr)	Platelet (×104/mm3)	Albumin (g/L)	ALT (nkat/L)
F 0	5	3/2	35	19.9	42	182.6
			(29-39)	(14.4-26.0)	(3.2-4.6)	(7-84)
F 1	27	17/10	51	15.8	41	1477.4
			(31-73)	(10.3-25.2)	(3.6-4.7)	(20-267)
F 2	13	8/5	57	13	39	1543.8
			(50-64)	(10.0-15.1)	(3.5-4.5)	(31-235)
F 3	34	22/12	55	12.2	39	1062.4
			(30-68)	(8.3-19.1)	(3.3-4.3)	(23-295)
F 4	30	12/18	59	9.5	34	996
			(43-75)	(3.2-21.3)	(2.5-4.1)	(13-150)

M: male, F: female.

Table 2 Correlation between type IV collagen, PIIIP, HA, YKL-40 and parameters of liver function.

	Type IV collagen	PIIIP	Hyaluronic acid	YKL-40
Type IV collagen		0.432b	0.25	0.258
PIIIP	0.432b		0.333	0.367
Hyaluronic acid	0.25	0.333		0.536bd
YKL-40	0.258	0.258	0.536bd
Platelet	-0.453b	-0.105	-0.494b	-0.478b
Albumin	-0.091	0.127	-0.472b	-0.239
ALT	0.149	-0.046	-0.108	0.009

^bP<0.001,

^dP<0.0001.

Table 3 Prediction of cirrhosis vs chronic hepatitis C by hyaluronic acid and YKL-40.

	Cut-off value	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)
IV collagen (ng/mL)	6.55	60	61	61	60
PIIIP (U/mL)	0.995	77	66	69	67
HA (ng/mL)	183.5	80	80	80	80
YKL-40 (ng/mL)	284.8	80	71	73	78

Table 4 Prediction of severe hepatitis C versus mild hepatitis C by hyaluronic acid and YKL-40.

	Cut-off value	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)
IV collagen (ng/mL)	5.75	65	69	67	66
PIIIP (U/mL)	0.835	78	75	76	77
HA (ng/mL)	75.7	75	81	79	76
YKL-40 (ng/mL)	186.4	78	81	80	79